Related Experiment Video
Updated: Nov 9, 2025

Generation of Murine Cardiac Pacemaker Cell Aggregates Based on ES-Cell-Programming in Combination with Myh6-Promoter-Selection
Published on: February 17, 2015
Targeting Son of Sevenless 1: The pacemaker of KRAS
Dirk Kessler1, Daniel Gerlach1, Norbert Kraut1
1Discovery Research, Boehringer Ingelheim Regional Center Vienna GmbH & Co KG, 1120, Vienna, Austria.
Abstract:
Son of Sevenless (SOS) is a guanine nucleotide exchange factor that activates the important cell signaling switch KRAS. SOS acts as a pacemaker for KRAS, the beating heart of cancer, by catalyzing the "beating" from the KRAS(off) to the KRAS(on) conformation. Activating mutations in SOS1 are common in Noonan syndrome and oncogenic alterations in KRAS drive 1 in seven human cancers. Promising clinical efficacy has been observed for selective KRASG12C inhibitors, but the vast majority of oncogenic KRAS alterations remain undrugged. The discovery of a druggable pocket on SOS1 has led to potent SOS1 inhibitors such as BI-3406. SOS1 inhibition leads to antiproliferative effects against all major KRAS mutants. The first SOS1 inhibitor has entered clinical trials for KRAS-mutated cancers. In this review, we provide an overview of SOS1 function, its association with cancer and RASopathies, known SOS1 activators and inhibitors, and a future perspective is provided.
Insights
Son of Sevenless (SOS) protein regulates KRAS, a key cancer driver. New SOS1 inhibitors show promise for treating KRAS-mutated cancers and RASopathies, with one now in clinical trials.
Area of Science:
- Molecular Biology
- Oncology
- Biochemistry
Background:
- Son of Sevenless (SOS) is a guanine nucleotide exchange factor crucial for KRAS signaling.
- Activating SOS1 mutations are linked to Noonan syndrome, and KRAS alterations drive numerous cancers.
- While KRASG12C inhibitors show efficacy, most KRAS mutations remain untargeted.
Purpose of the Study:
- To review the function of SOS1 in cell signaling.
- To discuss the role of SOS1 and KRAS in cancer and RASopathies.
- To provide an overview of SOS1 inhibitors and their therapeutic potential.
Main Methods:
- Literature review of SOS1 function, activators, and inhibitors.
- Analysis of SOS1's role in KRAS activation and its implications in disease.
- Discussion of emerging SOS1-targeted therapies.
Main Results:
- SOS1 inhibition demonstrates antiproliferative effects across various KRAS mutants.
- Discovery of druggable pockets on SOS1 has led to potent inhibitors like BI-3406.
- The first SOS1 inhibitor has advanced to clinical trials for KRAS-mutated cancers.
Conclusions:
- SOS1 is a critical regulator of KRAS and a promising therapeutic target.
- Targeting SOS1 offers a potential strategy for treating a broad spectrum of KRAS-driven cancers.
- Further research into SOS1 inhibitors may unlock new treatments for RASopathies and cancers.
More Related Videos
10:58Targeted Neuronal Injury for the Non-Invasive Disconnection of Brain Circuitry
Published on: September 27, 2020
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
Related Concept Videos
The Ras Gene
Ras is a...
Cardiac Action Potential
The cardiac action potential process involves a series of phases characterized by the movement of ions across the cardiac cell membranes, leading to the depolarization and repolarization of the cardiac myocytes.
Ionic Basis of Cardiac Action Potentials
Series Resonance
MOS Capacitor
The metal gate is typically made from highly conductive materials such as aluminum or polysilicon. Beneath the metal gate lies a thin layer of...
Receptor Tyrosine Kinases
Pulse rhythm
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac...